$ATRA on NASDAQ
January 08, 2024
Atara Biotherapeutics Announces $15 Million Registered Direct Offering
January 08, 2024
Atara Biotherapeutics to Present Recent Progress and Key Upcoming Milestones at the 42nd Annual J.P. Morgan Healthcare Conference
January 04, 2024
Atara Biotherapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
December 20, 2023
Atara Biotherapeutics Announces Closing of Expanded Global Tab-cel® Partnership with Pierre Fabre Laboratories
December 11, 2023
Atara Biotherapeutics Presents Positive Preclinical Data on ATA3431, A Next-Generation Allogeneic CD20/CD19-Targeted CAR, at the 65th ASH Annual Meeting
December 01, 2023
Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 29, 2023
Atara Biotherapeutics To Present Positive New Tab-cel® Clinical Data During Oral Session at ESMO Immuno-Oncology Annual Congress 2023
November 22, 2023
Atara Biotherapeutics to Participate at the 6th Annual Evercore ISI HealthCONx Conference
November 10, 2023
Atara Biotherapeutics To Participate at the Stifel Healthcare Conference
November 08, 2023
Atara Biotherapeutics Announces Primary Analysis Data from Phase 2 EMBOLD Clinical Trial of ATA188 in Non-Active Progressive Multiple Sclerosis
November 01, 2023
Atara Biotherapeutics Announces Expanded Global Tab-cel® Partnership with Pierre Fabre Laboratories and Third Quarter 2023 Financial Results
October 06, 2023
Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 19, 2023
Atara Biotherapeutics Announces Plans to Submit Tab-cel® BLA in Q2 2024 Following FDA Agreement on Comparability
September 01, 2023
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
August 31, 2023
Atara Biotherapeutics to Participate in Cell Therapies in Autoimmune Panel Discussion at the Citi 18th Annual BioPharma Conference
August 08, 2023
Atara Biotherapeutics Announces Second Quarter 2023 Financial Results and Operational Progress
August 04, 2023
Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 01, 2023
Atara Biotherapeutics to Announce Second Quarter 2023 Financial Results on Tuesday, August 8, 2023
July 31, 2023
Atara Biotherapeutics to Participate in the Canaccord Genuity 43rd Annual Growth Conference
July 07, 2023
Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 07, 2023
Atara Biotherapeutics to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference
June 05, 2023
Atara Biotherapeutics Presents Updated Tab-cel® Clinical Effectiveness Data at ASCO 2023
June 02, 2023
Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 08, 2023
Atara Biotherapeutics Announces First Quarter 2023 Financial Results and Operational Progress
May 05, 2023
Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 01, 2023
Atara Biotherapeutics to Announce First Quarter 2023 Financial Results on Monday, May 8, 2023
March 31, 2023
Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 03, 2023
Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 01, 2023
Atara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Cowen 43rd Annual Health Care Conference
February 21, 2023
Atara Biotherapeutics to Participate in the H.C. Wainwright Cell Therapy Virtual Conference
February 08, 2023
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Operational Progress
February 08, 2023
Pierre Fabre to Commercialize and Distribute the First Approved Allogeneic T-cell Immunotherapy in Europe Following Transfer of the European Commission Marketing Authorization of EBVALLO™ (tabelecleucel)
February 06, 2023
Atara Biotherapeutics to Announce Fourth Quarter and Full Year 2022 Financial Results on Wednesday, February 8, 2023
February 03, 2023
Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 13, 2023
Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
January 04, 2023
Atara Biotherapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
December 20, 2022
Atara Biotherapeutics Announces $31 Million Royalty Interest Financing Agreement with HealthCare Royalty
December 19, 2022
Atara Biotherapeutics Announces Changes to Its Board of Directors
December 19, 2022
Atara Biotherapeutics’ Ebvallo™ (tabelecleucel) Receives European Commission Approval as First Ever Therapy for Adults and Children with EBV+ PTLD
December 15, 2022
Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
December 12, 2022
Atara Biotherapeutics Presents Updated Clinical Data from Pivotal Phase 3 Trial (ALLELE) of Tab-cel® at the 64th American Society of Hematology (ASH) Annual Meeting
December 02, 2022
Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
November 23, 2022
Atara Biotherapeutics to Participate at the Evercore ISI 5th Annual HealthCONx Conference
November 09, 2022
Atara Biotherapeutics to Participate at the Stifel Healthcare Conference
November 08, 2022
Atara Biotherapeutics Announces Third Quarter 2022 Financial Results and Operational Progress
November 04, 2022
Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
November 01, 2022
Atara Biotherapeutics to Announce Third Quarter 2022 Financial Results on Tuesday, November 8, 2022
October 26, 2022
Atara Biotherapeutics Presents New MRI and Updated Open-Label Extension Data from Phase 1 Study of ATA188 in Progressive Multiple Sclerosis at ECTRIMS 2022
October 14, 2022
CHMP Recommends Approval of Atara Biotherapeutics’ Ebvallo™ (tabelecleucel) for the Treatment of Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease
October 10, 2022
Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- No Recent Filings Found.
